TRT Monitoring
What Should Happen vs What Often Does, Guideline Standards, Mystery-Shopper Evidence, and the 50x Markup
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Monitoring is standard of care for FDA-approved testosterone therapy
Reference only. Not medical advice.
This is something to take to a clinician. The Atlas can tell you what is known about trt monitoring in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
TRT requires structured monitoring because its main physiological risk, polycythemia, is silent until measured. This entry sets out what the Endocrine Society recommends (testosterone, hematocrit, PSA, lipids, blood pressure on a defined schedule) and contrasts it with documented telehealth practice: the Dubin 2022 mystery-shopper study, a 2025 JAMA investigation, and the roughly 50x price markup reported by KFF Health News.
Built to the standard of a clinical practice guideline, then measured against what the telehealth market actually delivers.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
- Endocrine Society monitoring (what should happen)
- Total testosterone at 3-6 months then annually; hematocrit at 3-6 months; PSA at 3-6 months if over 40 then annual; bone density at baseline and 1-2 years if osteoporosis indicated; lipid panel; blood pressure (especially oral)
- What some platforms provide (what often does)
- Variable. Hone Health's CEO stated 90-day testing in a CBS News investigation; testing adequacy varies dramatically by platform
How it works
Testosterone stimulates erythropoiesis, raising hematocrit; viscosity and thrombotic risk climb as hematocrit exceeds ~54%, triggering dose reduction or cessation. Testosterone can lower HDL and, with oral undecanoate, raise blood pressure. In men over 40 the prostate is monitored with PSA. Because none of these changes are symptomatic early, scheduled labs are the only way to catch them, which is precisely the function a low-touch subscription model can underprovide.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks. Changes to hormones, sexual function, or sexual health warrant evaluation by a qualified healthcare provider.
Replacement is not the same as a cycle
Without consistent trough-level monitoring, men can sit at supraphysiological peaks without knowing it. A 200 mg/week dose in a non-deficient man may exceed 1500 ng/dL at peak, anabolic territory. Monitoring is what keeps replacement physiological.
What it does to fertility
Monitoring should include attention to fertility intent. The Dubin study's central finding, clinics prescribing TRT to a man wanting children, illustrates how inadequate monitoring and intake screening can lead to inappropriate suppression of spermatogenesis. Men wishing to preserve fertility need LH/FSH assessment and alternatives discussed before starting.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Total testosterone at 3-6 months then annually
- Hematocrit / CBC at 3-6 months (and at any dose change)
- PSA at 3-6 months if over 40, then annual prostate monitoring
- Lipid panel (HDL can fall)
- Blood pressure (especially oral undecanoate)
- Bone density at baseline and 1-2 years if osteoporosis indicated
What people get wrong
Often saidMy telehealth subscription's convenience means the monitoring is fine
ActuallyConvenience and clinical rigor are not the same. The recurring-subscription model creates structural pressure toward prescribing and away from stopping; documented practice ranges from adequate to inadequate, with the Dubin study showing 6 of 7 clinics prescribing inappropriately.
Who profits, and who pushes back
Bradley Anawalt
Argues that low-touch prescribing without confirmed biochemical hypogonadism and scheduled labs medicalizes normal aging and exposes men to unmonitored risk.
Joshua Sharfstein
Has flagged direct-to-consumer hormone telehealth as prone to demand-driven prescribing that can outpace appropriate safety monitoring.
Monitoring-minimalist clinicians
Contend that for many stable patients the full Endocrine Society lab cadence is more intensive than the modest absolute risk justifies, and that hematocrit alone captures most actionable harm.
Set against the alternatives
Compared with the unmonitored or self-directed testosterone use common in gray-market and influencer channels, guideline-based monitoring trades convenience for safety: it adds scheduled hematocrit, PSA, lipid and blood-pressure checks that catch silent polycythemia and prostate signals before they become symptomatic. Compared with the lighter-touch monitoring some telehealth subscriptions provide, the Endocrine Society schedule is more conservative; critics on one side call low-touch models inadequate, while monitoring-minimalists argue hematocrit surveillance captures most actionable harm. Ēnel positions structured monitoring as the dividing line between therapeutic replacement and a low-oversight commodity product.
| Parameter | When | Threshold / action | Why |
|---|---|---|---|
| Total testosterone | 3-6 mo, then annual | Target mid-normal range | Confirm adequate dosing |
| Hematocrit | Baseline, 3-6 mo, annual | Stop if >54% | Silent polycythemia risk |
| PSA + DRE | Baseline, 3-12 mo | Evaluate rise; urology referral | Prostate safety (men >40) |
| Lipids / blood pressure | Baseline, periodically | Watch HDL drop, BP rise | Cardiovascular surveillance |
| Symptoms / adherence | Each visit | Reassess need to continue | Avoid unmonitored use |
What we do not know
- What minimal monitoring cadence safely captures most actionable harm in stable, low-risk men?
- Does the 54% hematocrit cutoff reflect real thrombotic risk, or is it a conservative legacy threshold?
- How much does asynchronous telehealth degrade actual lab follow-through versus in-person care?
- Can at-home or point-of-care hematocrit testing close the monitoring gap in subscription models?
- What is the true long-term cardiovascular and prostate signal under modern CDC-harmonized dosing?
What could change
At-home hematocrit/lab kitsMail-in and point-of-care testing to restore monitoring in remote-care modelsAlgorithmic lab-overdue flagsTelehealth platforms automating recall when scheduled labs lapseRegulatory scrutinyGrowing attention to DTC hormone prescribing standards and monitoring adequacyOutcome registriesReal-world data on cardiovascular and prostate events under contemporary TRT
At a glance
- Primary safety risk
- Polycythemia (testosterone stimulates erythropoiesis)
- First recheck
- Testosterone and hematocrit at 3-6 months
- PSA
- At 3-6 months if over 40, then annually
- Markup reported
- ~50x ($0.027/mg ASP vs $1.55/mg equivalent online)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about TRT Monitoring. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Dubin et al. mystery-shopper study2022
A standardized 'patient' with normal testosterone and a stated desire for fertility presented to 7 online TRT clinics; 6 of 7 prescribed testosterone despite the fertility contraindication and the absence of deficiency
JAMA telehealth investigation2025
Reported that some direct-to-consumer platforms did not consistently convey treatment risks or conduct comprehensive diagnostic testing before initiating TRT
KFF Health News / CBS News markup analysis2024
Injectable testosterone cypionate at ~$0.027/mg Medicare average sales price was sold online at ~$1.55/mg equivalent, about a 50x markup